Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Schuster

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
British Journal of Haematology|November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyStephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2010
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationS A Giralt, K F Mangan, R T Maziarz, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
British Journal of Haematology|November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyStephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2010
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationS A Giralt, K F Mangan, R T Maziarz, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 20